Similarly, the incidence of most immune-mediated adverse events was not higher with pembrolizumab-combination therapy than that previously observed with pembrolizumab monotherapy. 12, 14, 20 The exception may be nephritis and acute kidney injury, both of which are also associated with pemetrexed 30 and platinum-based drugs 31 and occurred with a greater frequency in this trial than in earlier trials of pembrolizumab monotherapy. 12, 14, 20